We make medical countermeasures that address natural, accidental and intentional public health threats. Our products target biological and chemical threats, as well as emerging infectious diseases.
Strengthening Our Anthrax Franchise
Emergent BioSolutions Completes Acquisition of Raxibacumab from GlaxoSmithKline